Evidence map›Paper›PMID 39075404›Full record

ArticleBMC cancer2024

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Pilar Barretina-Ginesta, Marta Gil-Martin, Elena Garralda, Joaquim Bosch-Barrera, Teresa Morán and 16 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Alexandra LearyMedical Oncology, Institut Gustave Roussy, Villejuif, France.
Purificación Estévez-GarcíaMedical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Renaud SabatierDepartment of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.
Isabelle Ray-CoquardMedical Oncology, Centre Léon Bérard, Lyon, France.
Margarita RomeoDepartment of Medical Oncology, Department of Medicine, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
Pilar Barretina-GinestaMedical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d'Oncologia (ICO), Medical School University of Girona (UdG), Girona, Spain.
Marta Gil-MartinMedical Oncology, Catalan Institute of Oncology and IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
Elena GarraldaMedical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Joaquim Bosch-BarreraMedical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d'Oncologia (ICO), Medical School University of Girona (UdG), Girona, Spain.
Teresa MoránDepartment of Medical Oncology, Department of Medicine, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
Paloma Martin-MartorellMedical Oncology, INCLIVA-Hospital Clínico Universitario, Valencia, Spain.
Ernest NadalMedical Oncology, Catalan Institute of Oncology and IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
Pere GascónMedical Oncology Service, Hospital Clínic. Universitat de Barcelona, Barcelona, Spain.
Jordi RodonEarly Drug Development, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Jose M LizcanoDepartment of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
Pau Muñoz-GuardiolaDepartment of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
Gemma Fierro-DuránResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Oriol Pedrós-GámezResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Héctor Pérez-MontoyoResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Marc Yeste-VelascoResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Marc CortalResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Antonio Pérez-CamposResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Jose AlfonResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
Carles DomenechResearch and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain. carles.domenech@abilitypharma.com.
Alejandro Pérez-Fidalgo *Medical Oncology, INCLIVA-Hospital Clínico Universitario, Valencia, Spain.
Ana Oaknin *Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39075404
PMCPMC11285527

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.